- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03597321
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML (ELIT-AML01)
July 24, 2018 updated by: Institut Paoli-Calmettes
Comparative Phase II Trial of Early Prophylactic Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Myeloid Leukemia
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for patients with acute myeloid leukemia (AML).
However, transplantation related toxicity and mortality as well as the existence of HLA identical sibling donor represent major limitations.
Over the 20 past years, the development of reduced intensity conditioning (RIC) regimen and the use of alternative donors allowed extending the possibility of Allo-HSCT for AML, with decreased toxicity and mortality.
This invited to propose this strategy to more advanced patients, making that AML recurrence has become one of the main issues after Allo-HSCT.
Thus, to develop prophylactic and preemptive strategies to minimize disease recurrence after Allo-HSCT is now the main challenge in the field.
Among cellular and/or pharmacological treatments after Allo-HSCT, donor lymphocyte infusion (DLI) is probably one of the most commonly used treatments after Allo-HSCT.
Indeed, DLI were reported as a potential efficient immunotherapy more than 20 years ago for the treatment of patients with leukemia relapsing after Allo-HSCT.
However, most of experiences were reported in the setting of relapse after Allo-HSCT and no prospective evaluation of prophylactic DLI is available so far.
Thus no strong recommendation for the use of DLI after Allo-HSCT can be made.
Our study proposal would like to assess the question of prophylactic DLI efficacy, as a proof of concept of early immune intervention after Allo-HSCT.
The investigators, therefore, designed a prospective multicenter randomized trial evaluating the impact of early DLI on outcome after Allo-HSCT for AML.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
124
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bouches Du Rhône
-
Marseille, Bouches Du Rhône, France, 13009
- Institut Paoli-Calmettes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- AML in hematological complete remission at the time of inclusion
- Patient age from 18 to 70.
- Able to comply with the protocol.
- Written informed consent.
- Allogeneic stem cell transplantation from any donor except cord blood.
- Unmanipulated bone marrow or peripheral blood stem cells as graft source are allowed
- Ongoing GVHD prophylaxis using cyclosporin A at the time of inclusion.
Exclusion Criteria:
- Presence or history of grade 2 to 4 acute GVHD.
- No hematological CR of AML at the time of inclusion. CR patients positive with molecular or phenotypic minimal residual disease (MRD) can be included.
- Pregnancy/breast feeding.
- Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
- Concomitant uncontrolled disease and/or organ dysfunction (infection, severe heart, renal, respiratory or hepatic failure…).
- Primary or secondary graft failure.
- Previous solid organ allogeneic transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm A-DLI
Patients will be planned to receive prophylactic Donor Lymphocyte Injection
|
DLI will be collected from the donor by leukapheresis according to local standard procedures of each center.
Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines.
A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI.
DLI procedure will be performed according to local guidelines of each center.
|
NO_INTERVENTION: Arm B- No intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free survival (RFS) at 2 years after randomization
Time Frame: 2 years
|
RElpase-free survival will be evaluated in an intent-to-treat analysis by Kaplan Meier estimate and Log Rank test.
Survival will be calculated from the date of randomization
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 1, 2019
Primary Completion (ANTICIPATED)
January 1, 2021
Study Completion (ANTICIPATED)
January 1, 2024
Study Registration Dates
First Submitted
July 16, 2018
First Submitted That Met QC Criteria
July 23, 2018
First Posted (ACTUAL)
July 24, 2018
Study Record Updates
Last Update Posted (ACTUAL)
July 26, 2018
Last Update Submitted That Met QC Criteria
July 24, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELIT-AML01-IPC 2017-006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on prophylactic donor lymphocyte infusion (DLI)
-
Abramson Cancer Center of the University of PennsylvaniaCompletedAcute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); MacroGenicsRecruitingRelapsed Acute Myeloid LeukemiaUnited States
-
University Hospital TuebingenRecruitingHematologic MalignancyGermany
-
National Cancer Institute (NCI)TerminatedHodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemias | Multiple Myeloma With PlasmacytomaUnited States
-
M.D. Anderson Cancer CenterZiopharm OncologyCompletedLymphoma | LeukemiaUnited States
-
Assistance Publique - Hôpitaux de ParisPierre and Marie Curie University; Paris 12 Val de Marne UniversityCompletedHematological MalignancyFrance
-
Sumithira VasuCompletedRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Minimal Residual DiseaseUnited States
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaboratorsCompletedHematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte InfusionChina
-
Masonic Cancer Center, University of MinnesotaCompletedAML | MDS | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, ChronicUnited States
-
Peking University People's HospitalUnknownAcute Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation | Minimal Residual Disease | Relapse | Donor Lymphocyte Infusion | Graft-versus-host DiseaseChina